Previous 10 | Next 10 |
HOUSTON, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize ® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that Peter Nielsen...
Bio-Path Holdings, Inc. (BPTH) Q2 2022 Earnings Conference Call August 16, 2022, 08:30 AM ET Company Participants Will O'Connor - Stern Investor Relations Peter Nielsen - CEO and CFO Anthony Price - SVP of Finance, Accounting and Administration Conference C...
Bio-Path press release ( NASDAQ: BPTH ): Q2 GAAP EPS of -$0.42 beats by $0.07 . As of June 30, 2022, the Company had cash of $17.0 million, compared to $23.8 million at December 31, 2021. For further details see: Bio-Path GAAP EPS of -$0.42 beats by $0.07
HOUSTON, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize ® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced its financial ...
HOUSTON, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize ® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a...
Bio Path Holdings Inc. (BPTH) Q1 2022 Results Conference Call May 17, 2022 8:30 AM ET Company Participants Peter Nielsen - President, CEO Anthony Price - SVP, Finance, Accounting & Administration Conference Call Participants Yi Chen - H.C. Wainwright Will O'Connor - Stern Investor Relatio...
Bio-Path press release (NASDAQ:BPTH): Q1 GAAP EPS of -$0.47 misses by $0.01. As of March 31, 2022, the Company had cash of $21.2 million, compared to $23.8 million as of December 31, 2021. For further details see: Bio-Path GAAP EPS of -$0.47 misses by $0.01
HOUSTON, May 17, 2022 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize ® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced its financial r...
AER, ALLT, BPTH, OTCPK:ENGIY, OTCQB:GAXY, HD, HUYA, OTCQX:IMBBY, JD, JMIA, KMDA, MDWD, OBSV, ONON, PTN, REE, RSKD, SE, VBLT, VOD, WMT, XNET For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings before Tuesday's open
HOUSTON, May 10, 2022 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize ® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a ...
News, Short Squeeze, Breakout and More Instantly...
Bio-Path Holdings Inc. Company Name:
BPTH Stock Symbol:
NASDAQ Market:
Bio-Path Holdings Inc. Website:
Marks Meaningful Progress Across Key Clinical Trials in Multiple Cancer Indications Completes Development of Oncology Molecular Biomarkers and Prepares for Preclinical Obesity Studies HOUSTON, July 08, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnolog...
2024-06-17 10:10:00 ET June 17, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing platform releases the first of a two-part series looking at developments for the treatment of blood cancers. Today's snapshot focuses in on acute myeloid leukemia (AML) and the compan...